The Jenner Institute is a research partnership between the University of Oxford and The Pirbright Institute.
The Institute focuses on the parallel development of human and vetinary vaccines against major global diseases - from early-stage research through to clinical trials.
Last year to mark World Tuberculosis Day NDM spoke to Professor Helen McShane to find out more about her research developing an improved TB vaccine. NDM spoke to her again to find out if there have been any developments in the last year.
Clinical trials are an essential part of vaccine development, and our volunteers play a critical role in our studies.
If you would like to find out more about paid clinical trials, and what is involved in participating, please go to our Recruiting Trials page to see which trials are currently recruiting.
Speaker to be confirmed: Structural insights into severe malaria’, 13 Apr 12:00
Transient IL-10 receptor blockade can enhance CD8(+) T cell responses to a simian adenovirus-vectored HIV-1 conserved region immunogen. Hum Vaccin Immunother
Identification of a novel three-domain KIR allele: KIR3DL1*087 using high-resolution molecular techniques. Tissue Antigens , 85 (2)